Mizuho analyst Anthony Petrone lowered the firm’s price target on Haemonetics (HAE) to $70 from $80 and keeps an Outperform rating on the shares. The firm lowered estimates and price targets for several names in its medical devices and diagnostics coverage ahead of Q1 earnings from the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics price target lowered to $84 from $88 at BTIG
- Haemonetics price target lowered to $64 from $70 at Citi
- Haemonetics: FDA Label Expansion and New Product Launches Poised to Reignite Vascular Closure Growth by FY27
- Haemonetics: FDA approves expanded labeling for VASCADE MVP XL system
- Haemonetics price target lowered to $70 from $75 at Citi